Within the EID laboratory also resides the bioinformatics analysis of raw data from sequencing. Preference will also be given to those who have obtained a… $4,840 - $6,237 a month
From State of Wyoming - Mon, 28 Dec 2020 20:52:22 GMT - View all Cheyenne, WY jobs

Funding Opportunity RFA-AA-21-001 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism intends to renew an initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for an R01 Clinical Trial Optional mechanism focusing on health disparities and health services. This FOA will include five areas of focus: access to treatment, making treatment more appealing, costs, dissemination and implementation, and health disparities. Applications are expected to emphasize health disparities in addition to the other four areas of emphasis.

Notice NOT-MH-21-115 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-21-040 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

Funding Opportunity RFA-DA-21-041 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

Competitive plus excellent benefits package: Wellcome Sanger Institute: The Opportunity: The Associate Director of Delivery and Operations is a key role on the Tree of Life Leadership team at the Wellcome Sanger Institu... Hinxton, Cambridgeshire

Please submit your resume, thoughtful cover letter, academic transcripts and contact for three professional/academic references to the online application page… $540 a week
From American Conservation Experience - EPIC - Thu, 24 Dec 2020 00:49:42 GMT - View all Onalaska, WI jobs

Please submit your resume, thoughtful cover letter, academic transcripts and contact for three professional/academic references to the online application page… $540 a week
From American Conservation Experience - EPIC - Thu, 24 Dec 2020 00:49:42 GMT - View all Onalaska, WI jobs

Competitve Salary: CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Bergthaler lab at CeMM is currently recruiting an experienced Senior Bioinformatician/Geneticist .... Vienna, Austria

Notice NOT-MH-21-175 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-120 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-005 from the NIH Guide for Grants and Contracts

Notice NOT-DK-21-004 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-051 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-103 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/?R?e?s?e?a?r?c?h staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-21-102 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving m?o?r?e? ?t?h?a?n? ?o?n?e? clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-21-101 from the NIH Guide for Grants and Contracts. NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-OD-21-045 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-044 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-21-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.